Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which numbing agent wins for a more comfortable throat scope?

NCT ID NCT07691346

Symptom relief Sponsor: General Hospital of Shenyang Military Region Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial compares two common throat-numbing medicines—dyclonine hydrochloride mucilage and tetracaine hydrochloride jelly—to see which one works better for reducing discomfort during an unsedated gastroscopy. About 208 adults scheduled for the procedure will receive one of the two numbing agents before the scope is inserted. The study measures pain, taste, nausea, and how well the medicine clears foam to help doctors choose the best option for patient comfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dyclonine hydrochloride mucilage and tetracaine hydrochloride jelly
What this could lead to
If one numbing agent proves better, it could become the standard choice for throat anesthesia during gastroscopy, making the procedure more comfortable for patients.
What could go wrong
This is a single-center trial with 208 participants, so results may not apply to all patients. The study compares two existing drugs, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 208 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-75 years, of either sex; * Scheduled for an unsedated gastroscopy; * American Society of Anesthesiologists (ASA) physical status class I or II; * Able to understand and cooperate with Visual Analogue Scale (VAS) comfort assessment; * Willing to provide written informed consent voluntarily. Exclusion Criteria: * Known allergy to the study agents; * Severe cardiopulmonary disease or hepatic/renal insufficiency; * Long-term use of sedatives or analgesics, or history of alcohol abuse; * Pregnancy or lactation; * Dysphagia or trismus (limited mouth opening); * Contraindications to upper gastrointestinal endoscopy, including acute perforation and active massive bleeding; * Mental or cognitive disorders that may preclude cooperation with the procedure; * Scheduled for therapeutic endoscopic procedures with an anticipated procedure time exceeding 15 minutes; * Altered upper gastrointestinal anatomy due to prior total gastrectomy, esophagectomy, or subtotal gastrectomy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal symptoms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal symptoms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Gastroenterology,General Hospital of Northern Theater Command

    Shenyang, Liaoning, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.